No­var­tis CEO Vas Narasimhan lines up his late-stage block­buster con­tenders — mix­ing old fa­vorites and add-ons

Every Big Phar­ma com­pa­ny is judged by its late-stage pipeline and the num­ber of prospec­tive block­busters in play. No­var­tis CEO Vas Narasimhan is giv­ing his piv­otal strat­e­gy top marks to­day as the gi­ant play­er re­views its de­vel­op­ment game plan in the wake of a cou­ple of key set­backs.

Adding it all up, No­var­tis is us­ing its R&D re­view to high­light a tal­ly of 26 block­busters in the pipeline, 13 projects in what is now grouped in­to cell, gene and ra­di­oli­gand work — adding ra­dio­phar­ma­ceu­ti­cals to the group — while aim­ing for 60 “ma­jor” reg­u­la­to­ry sub­mis­sions from 2019-2022. And it’s al­ready lin­ing up promised ap­provals for next year, bet­ting that they can shoot for key reg­u­la­to­ry OKs based on the da­ta in hand.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.